Allogene Therapeutics (ALLO) Expected to Announce Quarterly Earnings on Thursday

Allogene Therapeutics (NASDAQ:ALLO) is expected to announce its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $0.0020 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 5:00 PM ET.

Allogene Therapeutics Price Performance

Shares of ALLO stock opened at $2.53 on Thursday. Allogene Therapeutics has a fifty-two week low of $0.86 and a fifty-two week high of $2.80. The stock’s 50-day moving average is $1.78 and its two-hundred day moving average is $1.44. The firm has a market cap of $568.57 million, a P/E ratio of -2.58 and a beta of 0.50.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ALLO. Citizens Jmp raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research note on Friday, January 9th. Citigroup upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Friday, January 9th. UBS Group initiated coverage on shares of Allogene Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $8.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, February 22nd. Ten equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.40.

Insider Buying and Selling

In other news, SVP Earl Martin Douglas sold 22,900 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.76, for a total value of $40,304.00. Following the completion of the sale, the senior vice president directly owned 564,948 shares in the company, valued at approximately $994,308.48. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David D. Chang sold 95,269 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $1.80, for a total transaction of $171,484.20. Following the sale, the chief executive officer directly owned 5,185,862 shares of the company’s stock, valued at approximately $9,334,551.60. This represents a 1.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 222,987 shares of company stock worth $396,969 over the last ninety days. Company insiders own 13.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in Allogene Therapeutics by 177.9% during the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock valued at $8,547,000 after acquiring an additional 3,747,397 shares during the period. Kalehua Capital Management LLC bought a new position in shares of Allogene Therapeutics in the fourth quarter worth about $3,488,000. Patient Square Capital LP lifted its position in shares of Allogene Therapeutics by 66.5% during the 4th quarter. Patient Square Capital LP now owns 4,963,756 shares of the company’s stock worth $6,800,000 after purchasing an additional 1,982,360 shares during the last quarter. Millennium Management LLC lifted its position in shares of Allogene Therapeutics by 125.6% during the 3rd quarter. Millennium Management LLC now owns 3,390,026 shares of the company’s stock worth $4,204,000 after purchasing an additional 1,887,302 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in Allogene Therapeutics by 109.7% during the 3rd quarter. Two Sigma Investments LP now owns 3,383,644 shares of the company’s stock valued at $4,196,000 after purchasing an additional 1,770,419 shares during the period. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.